

GenIP[®]

10 June 2025

GenIP Plc
("GenIP" or the "Company")

Contract Win

GenIP Plc, a technology business providing Generative Artificial Intelligence (GenAI) services to help research organisations and corporations commercialise their innovations, is pleased to announce its expansion into the Republic of Chile through an engagement for 30 analytical assessment orders from a leading research institution.

This order increases the total value of Invention Evaluator orders received by GenIP since its IPO in October 2024 to over 850,000^[1].

Melissa Cruz, CEO of GenIP, commented:

"I am delighted to announce another new international contract with a leading research university, marking GenIP's first entry into the Chilean market. The institution has purchased 30 *Invention Evaluator* assessments, to support technology commercialisation decisions across its research portfolio. This milestone strengthens GenIP's growing footprint in Latin America and underscores global demand for its GenAI-enabled services.

"GenIP's global expansion is underpinned by a healthy balance sheet that allows the Company to capitalise on opportunities as they arise. As outlined in our audited results, the reported Operating Loss of 888,545 included 358,924 of share-based payments relating to the IPO that are not expected to recur. Customers typically pay in advance for Invention Evaluator report orders, providing the Company with operating cash flow and future revenue visibility, with revenue recognised upon completion and delivery of the report to the client. These factors help maintain the Company's strong financial position."

For further information regarding GenIP, please visit <https://genip.ai/>, or contact:

GenIP Plc

Melissa Cruz, CEO

Via Redchurch Communications

Beaumont Cornish Limited (Nominated Adviser)

Roland Cornish / Asia Szusciak / Andrew Price

Tel: +44 (0) 20 7628 3396

Novum Securities Limited (Broker)

Jon Belliss

Tel: +44 (0)20 7399 9425

JBelliss@novumsecurities.com

Redchurch Communications (Financial PR)

John Casey

genip@weareredchurch.com

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

Notes to Editors

About GenIP

GenIP provides generative artificial intelligence (GenAI) analytic services to help companies, research institutions and venture funds assess and commercialise new discoveries. GenIP combines expert human technical review with GenAI algorithms to provide insightful and verified services.

GenIP provides two complementary platform-based services:

1. Invention Evaluator: Provides bespoke research reports that assess the market potential of new technological innovations and discoveries using AI-driven proprietary software; and
2. Vetspoke, which is an executive recruitment platform that through advanced machine learning algorithms and

2. Vortechs: which is an executive recruitment platform that through advanced machine learning algorithms and natural language processing technologies assists in matching technology organisations with experienced executives skilled in technology commercialisation.

The Company believes that its integrated GenAI service offerings will help organisations to evaluate and commercialise their technological innovations.

Company Strategy

GenIP's goal is to be a leading Generative AI analytic services company. To achieve this, the Company has established three strategic pillars:

- Organically grow Invention Evaluator and Vortechs' revenue through institutional and corporate connections as well as increase client pipeline through marketing, advertising and social media spend.
- Expand the Generative AI service offerings within Invention Evaluator and Vortechs' to reach new customers and improve margins.
- Bolt-on acquisitions of additional Generative AI services that are helpful to our clients and have demonstrated initial market traction.

Forward looking statements

Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.

Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement. Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".

For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.

-ENDS-

[1] Orders are treated as pre-payments with revenue recognised upon report production by GenIP and delivery to the client. Typically, pre-payments are utilised approximately 50% within the first 12 months and the balance over the following 12-18 months.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CNTUKRRRVRUNRAR